View ValuationStratec 将来の成長Future 基準チェック /46Stratec利益と収益がそれぞれ年間36.6%と7.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に8.6% 38.8%なると予測されています。主要情報36.6%収益成長率38.75%EPS成長率Medical Equipment 収益成長13.5%収益成長率7.2%将来の株主資本利益率8.61%アナリストカバレッジGood最終更新日12 May 2026今後の成長に関する最新情報Price Target Changed • Aug 22Price target decreased by 7.9% to €37.32Down from €40.50, the current price target is an average from 6 analysts. New target price is 44% above last closing price of €26.00. Stock is down 41% over the past year. The company is forecast to post earnings per share of €1.27 for next year compared to €1.32 last year.お知らせ • May 31Stratec SE Confirms Consolidated Earnings Guidance for the Year 2025Stratec SE confirmed consolidated earnings guidance for the year 2025. Consolidated sales at constant currency expected to show growth in a low to medium single-digit percentage range Here, earnings contributions from Development and Services are expected to show significant intra-year growth in the fourth quarter of 2025 in particular.Price Target Changed • Apr 02Price target decreased by 13% to €45.50Down from €52.17, the current price target is an average from 6 analysts. New target price is 16% above last closing price of €39.25. Stock is down 37% over the past year. The company is forecast to post earnings per share of €1.84 for next year compared to €1.07 last year.Price Target Changed • Dec 18Price target decreased by 8.5% to €52.17Down from €57.00, the current price target is an average from 6 analysts. New target price is 28% above last closing price of €40.80. Stock is down 48% over the past year. The company is forecast to post earnings per share of €1.50 for next year compared to €2.41 last year.Price Target Changed • Jul 20Price target decreased by 19% to €60.67Down from €74.67, the current price target is an average from 6 analysts. New target price is 17% above last closing price of €51.80. Stock is down 44% over the past year. The company is forecast to post earnings per share of €1.84 for next year compared to €2.41 last year.Price Target Changed • Apr 14Price target decreased by 7.2% to €72.83Down from €78.50, the current price target is an average from 6 analysts. New target price is 17% above last closing price of €62.00. Stock is down 45% over the past year. The company is forecast to post earnings per share of €2.30 for next year compared to €2.41 last year.すべての更新を表示Recent updatesDeclared Dividend • May 20Dividend of €0.60 announcedDividend of €0.60 is the same as last year. Ex-date: 24th June 2026 Payment date: 26th June 2026 Dividend yield will be 3.5%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (71% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments.お知らせ • May 12Stratec SE, Annual General Meeting, Jun 23, 2026Stratec SE, Annual General Meeting, Jun 23, 2026, at 13:00 W. Europe Standard Time.お知らせ • Apr 29Stratec SE announces Annual dividend, payable on June 26, 2026Stratec SE announced Annual dividend of EUR 0.6000 per share payable on June 26, 2026, ex-date on June 24, 2026 and record date on June 25, 2026.お知らせ • Jan 02+ 3 more updatesStratec SE to Report Q1, 2026 Results on May 08, 2026Stratec SE announced that they will report Q1, 2026 results on May 08, 2026Price Target Changed • Aug 22Price target decreased by 7.9% to €37.32Down from €40.50, the current price target is an average from 6 analysts. New target price is 44% above last closing price of €26.00. Stock is down 41% over the past year. The company is forecast to post earnings per share of €1.27 for next year compared to €1.32 last year.Reported Earnings • Aug 19First half 2025 earnings released: EPS: €0.21 (vs €0.32 in 1H 2024)First half 2025 results: EPS: €0.21 (down from €0.32 in 1H 2024). Revenue: €118.6m (flat on 1H 2024). Net income: €2.60m (down 34% from 1H 2024). Profit margin: 2.2% (down from 3.3% in 1H 2024). Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 27% per year whereas the company’s share price has fallen by 32% per year.お知らせ • Jun 30Stratec Se Approves the Dividend, Payable on July 2, 2025Stratec SE at its Annual General Meeting held on June 27, 2025, the company will enable its shareholders to participate in the company’s performance by distributing a dividend of €0.60 per share for the past 2024 financial year (previous year’s dividend: €0.55 per share). The distribution total amounts to €7.3 million and will be paid to shareholders via their depositing banks on July 2, 2025.お知らせ • May 31Stratec SE Confirms Consolidated Earnings Guidance for the Year 2025Stratec SE confirmed consolidated earnings guidance for the year 2025. Consolidated sales at constant currency expected to show growth in a low to medium single-digit percentage range Here, earnings contributions from Development and Services are expected to show significant intra-year growth in the fourth quarter of 2025 in particular.お知らせ • May 21Stratec SE, Annual General Meeting, Jun 27, 2025Stratec SE, Annual General Meeting, Jun 27, 2025, at 14:00 W. Europe Standard Time.お知らせ • May 20Stratec SE announces Annual dividend, payable on July 02, 2025Stratec SE announced Annual dividend of EUR 0.6000 per share payable on July 02, 2025, ex-date on June 30, 2025 and record date on July 01, 2025.お知らせ • May 09Stratec SE(XTRA:SBS) dropped from Germany SDAX (Total Return) IndexStratec SE has been dropped from the Germany SDAX (Total Return) Indexお知らせ • May 07Stratec SE to Report Q1, 2025 Final Results on May 30, 2025Stratec SE announced that they will report Q1, 2025 final results on May 30, 2025お知らせ • Jan 10+ 2 more updatesStratec SE to Report Q3, 2025 Results on Nov 07, 2025Stratec SE announced that they will report Q3, 2025 results on Nov 07, 2025お知らせ • Dec 06Stratec SE to Report Fiscal Year 2024 Results on Mar 27, 2025Stratec SE announced that they will report fiscal year 2024 results on Mar 27, 2025Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: €0.045 (vs €0.42 in 3Q 2023)Third quarter 2024 results: EPS: €0.045 (down from €0.42 in 3Q 2023). Revenue: €57.2m (down 8.7% from 3Q 2023). Net income: €549.0k (down 89% from 3Q 2023). Profit margin: 1.0% (down from 8.2% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.New Risk • Sep 27New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 53% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 11Second quarter 2024 earnings released: EPS: €0.29 (vs €0.086 in 2Q 2023)Second quarter 2024 results: EPS: €0.29 (up from €0.086 in 2Q 2023). Revenue: €68.2m (up 5.7% from 2Q 2023). Net income: €3.48m (up 233% from 2Q 2023). Profit margin: 5.1% (up from 1.6% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.Upcoming Dividend • May 13Upcoming dividend of €0.55 per shareEligible shareholders must have bought the stock before 20 May 2024. Payment date: 22 May 2024. Payout ratio is a comfortable 55% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (1.8%).New Risk • Apr 30New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 11% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (11% operating cash flow to total debt). Minor Risk Profit margins are more than 30% lower than last year (4.8% net profit margin).Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: €0.037 (vs €0.11 in 1Q 2023)First quarter 2024 results: EPS: €0.037 (down from €0.11 in 1Q 2023). Revenue: €50.9m (down 16% from 1Q 2023). Net income: €447.0k (down 67% from 1Q 2023). Profit margin: 0.9% (down from 2.3% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.Price Target Changed • Apr 02Price target decreased by 13% to €45.50Down from €52.17, the current price target is an average from 6 analysts. New target price is 16% above last closing price of €39.25. Stock is down 37% over the past year. The company is forecast to post earnings per share of €1.84 for next year compared to €1.07 last year.Reported Earnings • Mar 29Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: €1.08 (down from €2.41 in FY 2022). Revenue: €261.9m (down 4.6% from FY 2022). Net income: €13.1m (down 55% from FY 2022). Profit margin: 5.0% (down from 11% in FY 2022). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 24%. Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 31% per year whereas the company’s share price has fallen by 30% per year.Declared Dividend • Mar 24Dividend of €0.55 announcedShareholders will receive a dividend of €0.55. Ex-date: 20th May 2024 Payment date: 22nd May 2024 Dividend yield will be 1.3%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (98% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 6.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 8.9% to bring the payout ratio under control. EPS is expected to grow by 102% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.Price Target Changed • Dec 18Price target decreased by 8.5% to €52.17Down from €57.00, the current price target is an average from 6 analysts. New target price is 28% above last closing price of €40.80. Stock is down 48% over the past year. The company is forecast to post earnings per share of €1.50 for next year compared to €2.41 last year.お知らせ • Dec 14+ 3 more updatesStratec SE to Report Q1, 2024 Results on Apr 26, 2024Stratec SE announced that they will report Q1, 2024 results on Apr 26, 2024お知らせ • Nov 29Stratec SE to Report Fiscal Year 2023 Results on Mar 21, 2024Stratec SE announced that they will report fiscal year 2023 results on Mar 21, 2024Valuation Update With 7 Day Price Move • Nov 04Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €46.30, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 61% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €56.48 per share.New Risk • Oct 29New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.7% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 98% Paying a dividend despite having no free cash flows. Minor Risk Profit margins are more than 30% lower than last year (4.7% net profit margin).Reported Earnings • Oct 29Third quarter 2023 earnings released: EPS: €0.42 (vs €1.00 in 3Q 2022)Third quarter 2023 results: EPS: €0.42 (down from €1.00 in 3Q 2022). Revenue: €62.7m (down 11% from 3Q 2022). Net income: €5.11m (down 58% from 3Q 2022). Profit margin: 8.2% (down from 17% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.Buying Opportunity • Oct 13Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 30%. The fair value is estimated to be €54.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.4% over the last 3 years. Earnings per share has declined by 6.5%. For the next 3 years, revenue is forecast to grow by 8.6% per annum. Earnings is also forecast to grow by 21% per annum over the same time period.New Risk • Aug 10New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows.Reported Earnings • Aug 10Second quarter 2023 earnings released: EPS: €0.086 (vs €0.12 in 2Q 2022)Second quarter 2023 results: EPS: €0.086 (down from €0.12 in 2Q 2022). Revenue: €64.5m (up 4.4% from 2Q 2022). Net income: €1.05m (down 27% from 2Q 2022). Profit margin: 1.6% (down from 2.3% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.Valuation Update With 7 Day Price Move • Jul 20Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €49.50, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total loss to shareholders of 49% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €86.13 per share.Price Target Changed • Jul 20Price target decreased by 19% to €60.67Down from €74.67, the current price target is an average from 6 analysts. New target price is 17% above last closing price of €51.80. Stock is down 44% over the past year. The company is forecast to post earnings per share of €1.84 for next year compared to €2.41 last year.お知らせ • Jun 09Stratec SE (XTRA:SBS) signed an agreement to acquire Natech Plastics, Inc. for $30 million.Stratec SE (XTRA:SBS) signed an agreement to acquire Natech Plastics, Inc. for $30 million on June 7, 2023. The transaction price agreed for the company, which has almost no debt, amounts to $30.0 million, plus a variable component (earn-out) based on defined performance criteria through to 2025. The transaction will be financed with a newly arranged credit line. In the 2022 financial year, its sales amounted to $16.3 million. The completion of the transaction, and thus first-time consolidation, are expected in July 2023.Upcoming Dividend • May 11Upcoming dividend of €0.97 per share at 1.6% yieldEligible shareholders must have bought the stock before 18 May 2023. Payment date: 22 May 2023. Payout ratio is a comfortable 61% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.7%). In line with average of industry peers (1.6%).Price Target Changed • Apr 14Price target decreased by 7.2% to €72.83Down from €78.50, the current price target is an average from 6 analysts. New target price is 17% above last closing price of €62.00. Stock is down 45% over the past year. The company is forecast to post earnings per share of €2.30 for next year compared to €2.41 last year.Reported Earnings • Apr 02Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: EPS: €2.41 (down from €3.30 in FY 2021). Revenue: €274.6m (down 4.4% from FY 2021). Net income: €29.2m (down 27% from FY 2021). Profit margin: 11% (down from 14% in FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.7%. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Price Target Changed • Mar 13Price target decreased by 15% to €80.17Down from €94.00, the current price target is an average from 6 analysts. New target price is 17% above last closing price of €68.50. Stock is down 35% over the past year. The company is forecast to post earnings per share of €2.68 for next year compared to €3.30 last year.Price Target Changed • Mar 03Price target decreased by 9.5% to €94.00Down from €104, the current price target is an average from 6 analysts. New target price is 23% above last closing price of €76.20. Stock is down 29% over the past year. The company is forecast to post earnings per share of €2.77 for next year compared to €3.30 last year.お知らせ • Jan 11+ 3 more updatesStratec SE to Report Fiscal Year 2022 Final Results on Mar 30, 2023Stratec SE announced that they will report fiscal year 2022 final results at 12:00 PM, Central European Standard Time on Mar 30, 2023Buying Opportunity • Nov 05Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 10%. The fair value is estimated to be €104, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 9.8% per annum. Earnings is also forecast to grow by 16% per annum over the same time period.Price Target Changed • Aug 25Price target decreased to €102Down from €114, the current price target is an average from 6 analysts. New target price is 18% above last closing price of €86.30. Stock is down 38% over the past year. The company is forecast to post earnings per share of €3.04 for next year compared to €3.30 last year.Reported Earnings • Aug 11Second quarter 2022 earnings released: EPS: €0.12 (vs €1.13 in 2Q 2021)Second quarter 2022 results: EPS: €0.12 (down from €1.13 in 2Q 2021). Revenue: €61.8m (down 26% from 2Q 2021). Net income: €1.43m (down 90% from 2Q 2021). Profit margin: 2.3% (down from 16% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 12%, compared to a 7.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.Price Target Changed • Aug 09Price target decreased to €112Down from €121, the current price target is an average from 5 analysts. New target price is 25% above last closing price of €89.40. Stock is down 33% over the past year. The company is forecast to post earnings per share of €3.04 for next year compared to €3.30 last year.Price Target Changed • Jul 26Price target decreased to €114Down from €125, the current price target is an average from 5 analysts. New target price is 19% above last closing price of €96.20. Stock is down 22% over the past year. The company is forecast to post earnings per share of €3.16 for next year compared to €3.30 last year.Upcoming Dividend • May 16Upcoming dividend of €0.95 per shareEligible shareholders must have bought the stock before 23 May 2022. Payment date: 25 May 2022. Payout ratio is a comfortable 29% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of German dividend payers (4.3%). Lower than average of industry peers (1.2%).Reported Earnings • May 06First quarter 2022 earnings: EPS in line with expectations, revenues disappointFirst quarter 2022 results: EPS: €0.92 (down from €0.95 in 1Q 2021). Revenue: €75.4m (up 4.7% from 1Q 2021). Net income: €11.2m (down 3.3% from 1Q 2021). Profit margin: 15% (down from 16% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 5.5%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 23% share price gain to €125, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 38x in the Medical Equipment industry in Germany. Total returns to shareholders of 95% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €139 per share.Price Target Changed • Apr 06Price target decreased to €126Down from €138, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of €126. Stock is up 8.6% over the past year. The company is forecast to post earnings per share of €3.08 for next year compared to €3.30 last year.Buying Opportunity • Apr 01Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be €135, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 50%. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings is also forecast to grow by 10% per annum over the same time period.Reported Earnings • Mar 31Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: €3.30 (up from €2.36 in FY 2020). Revenue: €287.3m (up 15% from FY 2020). Net income: €40.0m (up 41% from FY 2020). Profit margin: 14% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the next year, revenue is forecast to grow 6.4%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €104, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 31x in the Medical Equipment industry in Germany. Total returns to shareholders of 80% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €111 per share.Reported Earnings • Nov 14Third quarter 2021 earnings released: EPS €0.92 (vs €0.54 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €69.7m (up 17% from 3Q 2020). Net income: €11.2m (up 73% from 3Q 2020). Profit margin: 16% (up from 11% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.Price Target Changed • Nov 13Price target increased to €147Up from €132, the current price target is an average from 4 analysts. New target price is 14% above last closing price of €129. Stock is up 18% over the past year. The company is forecast to post earnings per share of €3.41 for next year compared to €2.36 last year.Reported Earnings • Aug 08Second quarter 2021 earnings released: EPS €1.13 (vs €0.64 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €83.8m (up 33% from 2Q 2020). Net income: €13.6m (up 78% from 2Q 2020). Profit margin: 16% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.お知らせ • May 21Stratec SE Approves Dividend for the Year 2020, Payable on May 26, 2021STRATEC SE at its Annual General Meeting held on May 20, 2021, approved to distribute a dividend of €0.90 per share to its shareholders for the past 2020 financial year (previous year: €0.84). The distribution total amounts to €10.9 million and will be paid out to shareholders through their depositing banks on May 26, 2021. This represents the seventeenth consecutive increase in the dividend since payment of the first dividend in 2004.Upcoming Dividend • May 14Upcoming dividend of €0.90 per shareEligible shareholders must have bought the stock before 21 May 2021. Payment date: 26 May 2021. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (1.1%).お知らせ • May 08Stratec SE Confirms Earnings Guidance for the Year 2021Stratec SE confirmed earnings guidance for the year 2021. For the 2021 financial year, STRATEC expects constant-currency sales growth at least in a high single-digit percentage range.Reported Earnings • May 08First quarter 2021 earnings released: EPS €0.95 (vs €0.37 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €72.0m (up 27% from 1Q 2020). Net income: €11.5m (up 157% from 1Q 2020). Profit margin: 16% (up from 8.0% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 28Stratec SE Provides Sales Guidance for the First Quarter of Fiscal Year 2021Stratec SE provided sales guidance for the first quarter of fiscal year 2021. For the quarter, the company expects consolidated sales of EUR 72.0 million.Reported Earnings • Apr 02Full year 2020 earnings released: EPS €2.36 (vs €1.34 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €250.1m (up 13% from FY 2019). Net income: €28.4m (up 77% from FY 2019). Profit margin: 11% (up from 7.3% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Mar 08New 90-day low: €108The company is down 9.0% from its price of €119 on 08 December 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €82.44 per share.Is New 90 Day High Low • Jan 23New 90-day high: €135The company is up 11% from its price of €122 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €98.43 per share.Price Target Changed • Jan 05Price target raised to €129Up from €119, the current price target is an average from 4 analysts. The new target price is close to the current share price of €123. As of last close, the stock is up 92% over the past year.お知らせ • Dec 23Stratec SE, Annual General Meeting, May 20, 2021Stratec SE, Annual General Meeting, May 20, 2021.お知らせ • Dec 19+ 3 more updatesStratec SE to Report First Half, 2021 Results on Aug 06, 2021Stratec SE announced that they will report first half, 2021 results on Aug 06, 2021お知らせ • Nov 27Stratec SE Names Stefanie Remmele as New Chairwoman of the Supervisory BoardAt its meeting held on November 26, the Supervisory Board of STRATEC SE elected Prof. Dr. Stefanie Remmele as the new Chairwoman of the Supervisory Board as of November 26, 2020. Prof. Dr. Remmele is Professor of Medical Technology at Landshut University of Applied Sciences and has been a member of the Supervisory Board at STRATEC SE since 2014. Prof. Dr. Stefanie Remmele will succeed the previous Chair, Dr. Frank Hiller. Given the recommendations made in the new version of the German Corporate Governance Code, Dr. Hiller, who is CEO of DEUTZ AG, Cologne, will in future be Deputy Chair of the Supervisory Board. The management would like to thank Dr. Hiller for his great commitment to the STRATEC Group in his role as Chairman of the Supervisory Board.Valuation Update With 7 Day Price Move • Nov 12Market pulls back on stock over the past weekAfter last week's 18% share price decline to €108, the stock is trading at a trailing P/E ratio of 49.5x, down from the previous P/E ratio of 60.4x. This compares to an average P/E of 50x in the Medical Equipment industry in Germany. Total returns to shareholders over the past three years are 75%.Analyst Estimate Surprise Post Earnings • Nov 07Revenue and earnings miss expectationsRevenue missed analyst estimates by 1.8%. Earnings per share (EPS) also missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 14%, compared to a 13% growth forecast for the Medical Equipment industry in Germany.Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS €0.54The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €59.7m (up 18% from 3Q 2019). Net income: €6.48m (up 116% from 3Q 2019). Profit margin: 11% (up from 5.9% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Oct 12New 90-day high: €130The company is up 41% from its price of €92.40 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €67.50 per share.業績と収益の成長予測DB:SBS - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028297201631412/31/2027286181831612/31/202626814243163/31/2026244-31024N/A12/31/20252510-170N/A9/30/202526015322N/A6/30/202526415726N/A3/31/2025266172543N/A12/31/2024258163149N/A9/30/2024256131834N/A6/30/2024258171633N/A3/31/202425212-116N/A12/31/202327015219N/A9/30/202325512-22-1N/A6/30/202326219-31-11N/A3/31/202326019-515N/A12/31/202227529-910N/A9/30/2022270281835N/A6/30/2022269273755N/A3/31/2022291403050N/A12/31/2021287404363N/A9/30/2021296464063N/A6/30/2021286412953N/A3/31/2021266352043N/A12/31/202025028632N/A9/30/202023524529N/A6/30/202022521-420N/A3/31/202022417-1215N/A12/31/201921414N/A21N/A9/30/201921214N/A8N/A6/30/201920714N/A13N/A3/31/201919511N/A9N/A12/31/201818811N/A12N/A9/30/201819316N/A20N/A6/30/201819723N/A28N/A3/31/201819824N/A28N/A12/31/201720727N/A30N/A9/30/201720828N/A30N/A6/30/201720620N/A21N/A3/31/201720319N/AN/AN/A12/31/201618519N/A16N/A9/30/201616614N/A17N/A6/30/201615519N/A23N/A3/31/201614421N/AN/AN/A12/31/201514722N/A26N/A9/30/201514722N/A35N/A6/30/201514621N/A35N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SBSは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 1.9% ) よりも高い成長率であると考えられます。収益対市場: SBS今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: SBS今後 3 年以内に収益を上げることが予想されます。収益対市場: SBSの収益 ( 7.2% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: SBSの収益 ( 7.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SBSの 自己資本利益率 は、3年後には低くなると予測されています ( 8.6 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 23:04終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Stratec SE 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Michael HeiderBerenbergJan KochDeutsche BankJan KochDeutsche Bank8 その他のアナリストを表示
Price Target Changed • Aug 22Price target decreased by 7.9% to €37.32Down from €40.50, the current price target is an average from 6 analysts. New target price is 44% above last closing price of €26.00. Stock is down 41% over the past year. The company is forecast to post earnings per share of €1.27 for next year compared to €1.32 last year.
お知らせ • May 31Stratec SE Confirms Consolidated Earnings Guidance for the Year 2025Stratec SE confirmed consolidated earnings guidance for the year 2025. Consolidated sales at constant currency expected to show growth in a low to medium single-digit percentage range Here, earnings contributions from Development and Services are expected to show significant intra-year growth in the fourth quarter of 2025 in particular.
Price Target Changed • Apr 02Price target decreased by 13% to €45.50Down from €52.17, the current price target is an average from 6 analysts. New target price is 16% above last closing price of €39.25. Stock is down 37% over the past year. The company is forecast to post earnings per share of €1.84 for next year compared to €1.07 last year.
Price Target Changed • Dec 18Price target decreased by 8.5% to €52.17Down from €57.00, the current price target is an average from 6 analysts. New target price is 28% above last closing price of €40.80. Stock is down 48% over the past year. The company is forecast to post earnings per share of €1.50 for next year compared to €2.41 last year.
Price Target Changed • Jul 20Price target decreased by 19% to €60.67Down from €74.67, the current price target is an average from 6 analysts. New target price is 17% above last closing price of €51.80. Stock is down 44% over the past year. The company is forecast to post earnings per share of €1.84 for next year compared to €2.41 last year.
Price Target Changed • Apr 14Price target decreased by 7.2% to €72.83Down from €78.50, the current price target is an average from 6 analysts. New target price is 17% above last closing price of €62.00. Stock is down 45% over the past year. The company is forecast to post earnings per share of €2.30 for next year compared to €2.41 last year.
Declared Dividend • May 20Dividend of €0.60 announcedDividend of €0.60 is the same as last year. Ex-date: 24th June 2026 Payment date: 26th June 2026 Dividend yield will be 3.5%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (71% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments.
お知らせ • May 12Stratec SE, Annual General Meeting, Jun 23, 2026Stratec SE, Annual General Meeting, Jun 23, 2026, at 13:00 W. Europe Standard Time.
お知らせ • Apr 29Stratec SE announces Annual dividend, payable on June 26, 2026Stratec SE announced Annual dividend of EUR 0.6000 per share payable on June 26, 2026, ex-date on June 24, 2026 and record date on June 25, 2026.
お知らせ • Jan 02+ 3 more updatesStratec SE to Report Q1, 2026 Results on May 08, 2026Stratec SE announced that they will report Q1, 2026 results on May 08, 2026
Price Target Changed • Aug 22Price target decreased by 7.9% to €37.32Down from €40.50, the current price target is an average from 6 analysts. New target price is 44% above last closing price of €26.00. Stock is down 41% over the past year. The company is forecast to post earnings per share of €1.27 for next year compared to €1.32 last year.
Reported Earnings • Aug 19First half 2025 earnings released: EPS: €0.21 (vs €0.32 in 1H 2024)First half 2025 results: EPS: €0.21 (down from €0.32 in 1H 2024). Revenue: €118.6m (flat on 1H 2024). Net income: €2.60m (down 34% from 1H 2024). Profit margin: 2.2% (down from 3.3% in 1H 2024). Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 27% per year whereas the company’s share price has fallen by 32% per year.
お知らせ • Jun 30Stratec Se Approves the Dividend, Payable on July 2, 2025Stratec SE at its Annual General Meeting held on June 27, 2025, the company will enable its shareholders to participate in the company’s performance by distributing a dividend of €0.60 per share for the past 2024 financial year (previous year’s dividend: €0.55 per share). The distribution total amounts to €7.3 million and will be paid to shareholders via their depositing banks on July 2, 2025.
お知らせ • May 31Stratec SE Confirms Consolidated Earnings Guidance for the Year 2025Stratec SE confirmed consolidated earnings guidance for the year 2025. Consolidated sales at constant currency expected to show growth in a low to medium single-digit percentage range Here, earnings contributions from Development and Services are expected to show significant intra-year growth in the fourth quarter of 2025 in particular.
お知らせ • May 21Stratec SE, Annual General Meeting, Jun 27, 2025Stratec SE, Annual General Meeting, Jun 27, 2025, at 14:00 W. Europe Standard Time.
お知らせ • May 20Stratec SE announces Annual dividend, payable on July 02, 2025Stratec SE announced Annual dividend of EUR 0.6000 per share payable on July 02, 2025, ex-date on June 30, 2025 and record date on July 01, 2025.
お知らせ • May 09Stratec SE(XTRA:SBS) dropped from Germany SDAX (Total Return) IndexStratec SE has been dropped from the Germany SDAX (Total Return) Index
お知らせ • May 07Stratec SE to Report Q1, 2025 Final Results on May 30, 2025Stratec SE announced that they will report Q1, 2025 final results on May 30, 2025
お知らせ • Jan 10+ 2 more updatesStratec SE to Report Q3, 2025 Results on Nov 07, 2025Stratec SE announced that they will report Q3, 2025 results on Nov 07, 2025
お知らせ • Dec 06Stratec SE to Report Fiscal Year 2024 Results on Mar 27, 2025Stratec SE announced that they will report fiscal year 2024 results on Mar 27, 2025
Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: €0.045 (vs €0.42 in 3Q 2023)Third quarter 2024 results: EPS: €0.045 (down from €0.42 in 3Q 2023). Revenue: €57.2m (down 8.7% from 3Q 2023). Net income: €549.0k (down 89% from 3Q 2023). Profit margin: 1.0% (down from 8.2% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.
New Risk • Sep 27New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 53% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 11Second quarter 2024 earnings released: EPS: €0.29 (vs €0.086 in 2Q 2023)Second quarter 2024 results: EPS: €0.29 (up from €0.086 in 2Q 2023). Revenue: €68.2m (up 5.7% from 2Q 2023). Net income: €3.48m (up 233% from 2Q 2023). Profit margin: 5.1% (up from 1.6% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • May 13Upcoming dividend of €0.55 per shareEligible shareholders must have bought the stock before 20 May 2024. Payment date: 22 May 2024. Payout ratio is a comfortable 55% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (1.8%).
New Risk • Apr 30New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 11% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (11% operating cash flow to total debt). Minor Risk Profit margins are more than 30% lower than last year (4.8% net profit margin).
Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: €0.037 (vs €0.11 in 1Q 2023)First quarter 2024 results: EPS: €0.037 (down from €0.11 in 1Q 2023). Revenue: €50.9m (down 16% from 1Q 2023). Net income: €447.0k (down 67% from 1Q 2023). Profit margin: 0.9% (down from 2.3% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
Price Target Changed • Apr 02Price target decreased by 13% to €45.50Down from €52.17, the current price target is an average from 6 analysts. New target price is 16% above last closing price of €39.25. Stock is down 37% over the past year. The company is forecast to post earnings per share of €1.84 for next year compared to €1.07 last year.
Reported Earnings • Mar 29Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: €1.08 (down from €2.41 in FY 2022). Revenue: €261.9m (down 4.6% from FY 2022). Net income: €13.1m (down 55% from FY 2022). Profit margin: 5.0% (down from 11% in FY 2022). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 24%. Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 31% per year whereas the company’s share price has fallen by 30% per year.
Declared Dividend • Mar 24Dividend of €0.55 announcedShareholders will receive a dividend of €0.55. Ex-date: 20th May 2024 Payment date: 22nd May 2024 Dividend yield will be 1.3%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (98% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 6.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 8.9% to bring the payout ratio under control. EPS is expected to grow by 102% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.
Price Target Changed • Dec 18Price target decreased by 8.5% to €52.17Down from €57.00, the current price target is an average from 6 analysts. New target price is 28% above last closing price of €40.80. Stock is down 48% over the past year. The company is forecast to post earnings per share of €1.50 for next year compared to €2.41 last year.
お知らせ • Dec 14+ 3 more updatesStratec SE to Report Q1, 2024 Results on Apr 26, 2024Stratec SE announced that they will report Q1, 2024 results on Apr 26, 2024
お知らせ • Nov 29Stratec SE to Report Fiscal Year 2023 Results on Mar 21, 2024Stratec SE announced that they will report fiscal year 2023 results on Mar 21, 2024
Valuation Update With 7 Day Price Move • Nov 04Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €46.30, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 61% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €56.48 per share.
New Risk • Oct 29New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.7% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 98% Paying a dividend despite having no free cash flows. Minor Risk Profit margins are more than 30% lower than last year (4.7% net profit margin).
Reported Earnings • Oct 29Third quarter 2023 earnings released: EPS: €0.42 (vs €1.00 in 3Q 2022)Third quarter 2023 results: EPS: €0.42 (down from €1.00 in 3Q 2022). Revenue: €62.7m (down 11% from 3Q 2022). Net income: €5.11m (down 58% from 3Q 2022). Profit margin: 8.2% (down from 17% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
Buying Opportunity • Oct 13Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 30%. The fair value is estimated to be €54.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.4% over the last 3 years. Earnings per share has declined by 6.5%. For the next 3 years, revenue is forecast to grow by 8.6% per annum. Earnings is also forecast to grow by 21% per annum over the same time period.
New Risk • Aug 10New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows.
Reported Earnings • Aug 10Second quarter 2023 earnings released: EPS: €0.086 (vs €0.12 in 2Q 2022)Second quarter 2023 results: EPS: €0.086 (down from €0.12 in 2Q 2022). Revenue: €64.5m (up 4.4% from 2Q 2022). Net income: €1.05m (down 27% from 2Q 2022). Profit margin: 1.6% (down from 2.3% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.
Valuation Update With 7 Day Price Move • Jul 20Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €49.50, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total loss to shareholders of 49% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €86.13 per share.
Price Target Changed • Jul 20Price target decreased by 19% to €60.67Down from €74.67, the current price target is an average from 6 analysts. New target price is 17% above last closing price of €51.80. Stock is down 44% over the past year. The company is forecast to post earnings per share of €1.84 for next year compared to €2.41 last year.
お知らせ • Jun 09Stratec SE (XTRA:SBS) signed an agreement to acquire Natech Plastics, Inc. for $30 million.Stratec SE (XTRA:SBS) signed an agreement to acquire Natech Plastics, Inc. for $30 million on June 7, 2023. The transaction price agreed for the company, which has almost no debt, amounts to $30.0 million, plus a variable component (earn-out) based on defined performance criteria through to 2025. The transaction will be financed with a newly arranged credit line. In the 2022 financial year, its sales amounted to $16.3 million. The completion of the transaction, and thus first-time consolidation, are expected in July 2023.
Upcoming Dividend • May 11Upcoming dividend of €0.97 per share at 1.6% yieldEligible shareholders must have bought the stock before 18 May 2023. Payment date: 22 May 2023. Payout ratio is a comfortable 61% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.7%). In line with average of industry peers (1.6%).
Price Target Changed • Apr 14Price target decreased by 7.2% to €72.83Down from €78.50, the current price target is an average from 6 analysts. New target price is 17% above last closing price of €62.00. Stock is down 45% over the past year. The company is forecast to post earnings per share of €2.30 for next year compared to €2.41 last year.
Reported Earnings • Apr 02Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: EPS: €2.41 (down from €3.30 in FY 2021). Revenue: €274.6m (down 4.4% from FY 2021). Net income: €29.2m (down 27% from FY 2021). Profit margin: 11% (down from 14% in FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.7%. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Price Target Changed • Mar 13Price target decreased by 15% to €80.17Down from €94.00, the current price target is an average from 6 analysts. New target price is 17% above last closing price of €68.50. Stock is down 35% over the past year. The company is forecast to post earnings per share of €2.68 for next year compared to €3.30 last year.
Price Target Changed • Mar 03Price target decreased by 9.5% to €94.00Down from €104, the current price target is an average from 6 analysts. New target price is 23% above last closing price of €76.20. Stock is down 29% over the past year. The company is forecast to post earnings per share of €2.77 for next year compared to €3.30 last year.
お知らせ • Jan 11+ 3 more updatesStratec SE to Report Fiscal Year 2022 Final Results on Mar 30, 2023Stratec SE announced that they will report fiscal year 2022 final results at 12:00 PM, Central European Standard Time on Mar 30, 2023
Buying Opportunity • Nov 05Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 10%. The fair value is estimated to be €104, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 9.8% per annum. Earnings is also forecast to grow by 16% per annum over the same time period.
Price Target Changed • Aug 25Price target decreased to €102Down from €114, the current price target is an average from 6 analysts. New target price is 18% above last closing price of €86.30. Stock is down 38% over the past year. The company is forecast to post earnings per share of €3.04 for next year compared to €3.30 last year.
Reported Earnings • Aug 11Second quarter 2022 earnings released: EPS: €0.12 (vs €1.13 in 2Q 2021)Second quarter 2022 results: EPS: €0.12 (down from €1.13 in 2Q 2021). Revenue: €61.8m (down 26% from 2Q 2021). Net income: €1.43m (down 90% from 2Q 2021). Profit margin: 2.3% (down from 16% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 12%, compared to a 7.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Aug 09Price target decreased to €112Down from €121, the current price target is an average from 5 analysts. New target price is 25% above last closing price of €89.40. Stock is down 33% over the past year. The company is forecast to post earnings per share of €3.04 for next year compared to €3.30 last year.
Price Target Changed • Jul 26Price target decreased to €114Down from €125, the current price target is an average from 5 analysts. New target price is 19% above last closing price of €96.20. Stock is down 22% over the past year. The company is forecast to post earnings per share of €3.16 for next year compared to €3.30 last year.
Upcoming Dividend • May 16Upcoming dividend of €0.95 per shareEligible shareholders must have bought the stock before 23 May 2022. Payment date: 25 May 2022. Payout ratio is a comfortable 29% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of German dividend payers (4.3%). Lower than average of industry peers (1.2%).
Reported Earnings • May 06First quarter 2022 earnings: EPS in line with expectations, revenues disappointFirst quarter 2022 results: EPS: €0.92 (down from €0.95 in 1Q 2021). Revenue: €75.4m (up 4.7% from 1Q 2021). Net income: €11.2m (down 3.3% from 1Q 2021). Profit margin: 15% (down from 16% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 5.5%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 23% share price gain to €125, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 38x in the Medical Equipment industry in Germany. Total returns to shareholders of 95% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €139 per share.
Price Target Changed • Apr 06Price target decreased to €126Down from €138, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of €126. Stock is up 8.6% over the past year. The company is forecast to post earnings per share of €3.08 for next year compared to €3.30 last year.
Buying Opportunity • Apr 01Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be €135, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 50%. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings is also forecast to grow by 10% per annum over the same time period.
Reported Earnings • Mar 31Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: €3.30 (up from €2.36 in FY 2020). Revenue: €287.3m (up 15% from FY 2020). Net income: €40.0m (up 41% from FY 2020). Profit margin: 14% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the next year, revenue is forecast to grow 6.4%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €104, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 31x in the Medical Equipment industry in Germany. Total returns to shareholders of 80% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €111 per share.
Reported Earnings • Nov 14Third quarter 2021 earnings released: EPS €0.92 (vs €0.54 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €69.7m (up 17% from 3Q 2020). Net income: €11.2m (up 73% from 3Q 2020). Profit margin: 16% (up from 11% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Nov 13Price target increased to €147Up from €132, the current price target is an average from 4 analysts. New target price is 14% above last closing price of €129. Stock is up 18% over the past year. The company is forecast to post earnings per share of €3.41 for next year compared to €2.36 last year.
Reported Earnings • Aug 08Second quarter 2021 earnings released: EPS €1.13 (vs €0.64 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €83.8m (up 33% from 2Q 2020). Net income: €13.6m (up 78% from 2Q 2020). Profit margin: 16% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
お知らせ • May 21Stratec SE Approves Dividend for the Year 2020, Payable on May 26, 2021STRATEC SE at its Annual General Meeting held on May 20, 2021, approved to distribute a dividend of €0.90 per share to its shareholders for the past 2020 financial year (previous year: €0.84). The distribution total amounts to €10.9 million and will be paid out to shareholders through their depositing banks on May 26, 2021. This represents the seventeenth consecutive increase in the dividend since payment of the first dividend in 2004.
Upcoming Dividend • May 14Upcoming dividend of €0.90 per shareEligible shareholders must have bought the stock before 21 May 2021. Payment date: 26 May 2021. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (1.1%).
お知らせ • May 08Stratec SE Confirms Earnings Guidance for the Year 2021Stratec SE confirmed earnings guidance for the year 2021. For the 2021 financial year, STRATEC expects constant-currency sales growth at least in a high single-digit percentage range.
Reported Earnings • May 08First quarter 2021 earnings released: EPS €0.95 (vs €0.37 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €72.0m (up 27% from 1Q 2020). Net income: €11.5m (up 157% from 1Q 2020). Profit margin: 16% (up from 8.0% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 28Stratec SE Provides Sales Guidance for the First Quarter of Fiscal Year 2021Stratec SE provided sales guidance for the first quarter of fiscal year 2021. For the quarter, the company expects consolidated sales of EUR 72.0 million.
Reported Earnings • Apr 02Full year 2020 earnings released: EPS €2.36 (vs €1.34 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €250.1m (up 13% from FY 2019). Net income: €28.4m (up 77% from FY 2019). Profit margin: 11% (up from 7.3% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Mar 08New 90-day low: €108The company is down 9.0% from its price of €119 on 08 December 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €82.44 per share.
Is New 90 Day High Low • Jan 23New 90-day high: €135The company is up 11% from its price of €122 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €98.43 per share.
Price Target Changed • Jan 05Price target raised to €129Up from €119, the current price target is an average from 4 analysts. The new target price is close to the current share price of €123. As of last close, the stock is up 92% over the past year.
お知らせ • Dec 23Stratec SE, Annual General Meeting, May 20, 2021Stratec SE, Annual General Meeting, May 20, 2021.
お知らせ • Dec 19+ 3 more updatesStratec SE to Report First Half, 2021 Results on Aug 06, 2021Stratec SE announced that they will report first half, 2021 results on Aug 06, 2021
お知らせ • Nov 27Stratec SE Names Stefanie Remmele as New Chairwoman of the Supervisory BoardAt its meeting held on November 26, the Supervisory Board of STRATEC SE elected Prof. Dr. Stefanie Remmele as the new Chairwoman of the Supervisory Board as of November 26, 2020. Prof. Dr. Remmele is Professor of Medical Technology at Landshut University of Applied Sciences and has been a member of the Supervisory Board at STRATEC SE since 2014. Prof. Dr. Stefanie Remmele will succeed the previous Chair, Dr. Frank Hiller. Given the recommendations made in the new version of the German Corporate Governance Code, Dr. Hiller, who is CEO of DEUTZ AG, Cologne, will in future be Deputy Chair of the Supervisory Board. The management would like to thank Dr. Hiller for his great commitment to the STRATEC Group in his role as Chairman of the Supervisory Board.
Valuation Update With 7 Day Price Move • Nov 12Market pulls back on stock over the past weekAfter last week's 18% share price decline to €108, the stock is trading at a trailing P/E ratio of 49.5x, down from the previous P/E ratio of 60.4x. This compares to an average P/E of 50x in the Medical Equipment industry in Germany. Total returns to shareholders over the past three years are 75%.
Analyst Estimate Surprise Post Earnings • Nov 07Revenue and earnings miss expectationsRevenue missed analyst estimates by 1.8%. Earnings per share (EPS) also missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 14%, compared to a 13% growth forecast for the Medical Equipment industry in Germany.
Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS €0.54The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €59.7m (up 18% from 3Q 2019). Net income: €6.48m (up 116% from 3Q 2019). Profit margin: 11% (up from 5.9% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Oct 12New 90-day high: €130The company is up 41% from its price of €92.40 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €67.50 per share.